SynthesisEuropean journal of pediatrics2026
The epidemiology of metabolic dysfunction-associated steatotic liver disease among pediatric patients with type 2 diabetes: Systematic review and meta-analysis.
Synthesis in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MASLD as Complication of Diabetes.Diabetes · 2026Review
- Updates on paediatric MASLD: insights from an endocrine lens.Diabetologia · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is strongly associated with type 2 diabetes (T2D) in adults; however, its epidemiology in the pediatric population remains unclear. We conducted a systematic review and meta-analysis to estimate the prevalence of MASLD among children and adolescents with T2D. We systematically searched PubMed and Embase databases from inception until March 18, 2025 to identify observational studies investigating the prevalence of MASLD (diagnosed by liver biopsy, imaging methods, or blood-based biomarkers) in children and adolescents (aged ≤ 21 years) with T2D. Data from eligible studies were extracted, and meta-analysis was performed using a generalized linear mixed model. This study was registered in PROSPERO (ID CRD420251013625). Eighteen unique studies with 3926 pediatric patients with T2D were included. The pooled prevalence of MASLD in pediatric T2D was 36.61% (95% confidence interval [CI] 26.45 to 48.12), with substantial heterogeneity (I
conclusionsMASLD affects over one-third of pediatric patients with T2D. These findings support early liver health screening in this high-risk group. Future research is needed to validate non-invasive tests for liver disease assessment in pediatric diabetes care. WHAT IS KNOWN: • Type 2 diabetes (T2D) is a strong risk factor for metabolic dysfunction-associated steatotic liver disease (MASLD). • The epidemiology of MASLD in children and adolescents with T2D remains poorly characterized. WHAT IS NEW: • MASLD affects an estimated 36.61% of pediatric patients with T2D, with substantial variation according to the diagnostic modality used. • This high prevalence underscores the need for early liver health screening in pediatric T2D.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.